Urgent.News

the world's headlines, one feed

Health & Medicine

A COPD drug from China draws $115M in venture funding

Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

FMT Shows Promise for Peanut Allergy Tolerance in Phase I Trial

A small Phase I trial found that fecal microbiome transplantation (FMT) increased peanut tolerance in some adults with a peanut allergy, while mouse studies suggested the effect may depend on bile acid metabolites.

  • Phase I trial shows FMT increases peanut reactivity threshold in five participants.
  • Increased tolerogenic regulatory T cells and decreased type 2 helper T cells linked to tolerance.
  • Post-FMT microbiomes protect allergy-prone mice from food allergy.